Aranoza in the Treatment of Metastatic Neuroendocrine Tumors (NETs): Single Institution Experience Abstract #1275

Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ.
Aim(s): To evaluate the efficacy and safety of Aranoza in metastatic WD NETs
Materials and methods: We performed a prospective analysis of all pts treated with Aranoza (500 mg/m2 for 3 days every 3 weeks) at our center between July 2007 and July 2014. The median progression-free survival was calculated using Kaplan-Meier method. Treatment efficacy was evaluated according to RECIST
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: prof Vera Gorbunova

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result